Covered recipient · General Payments record
RICHARD T MILAZZO JR.
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2023
$2,563.47
- Reported across 155 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.90 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $64.86 | 3 |
| Novo Nordisk AS | $57.77 | 4 |
| Amgen Inc. | $51.20 | 3 |
| Exact Sciences Corporation | $48.93 | 2 |
| GlaxoSmithKline, LLC. | $33.74 | 2 |
| Abbott Laboratories | $22.68 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.77 | 1 |
| Acerta Pharma LLC | $17.52 | 1 |
| Astellas Pharma US Inc | $15.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.68 | 06/15/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1018788267 | CMS |
| ABBVIE INC. | $25.63 | 01/23/2023 | Food and Beverage | Undisputed | 06/30/2026 | 997915775 | CMS |
| ABBVIE INC. | $21.01 | 06/12/2023 | Food and Beverage | Undisputed | 06/30/2026 | 997915777 | CMS |
| ABBVIE INC. | $18.22 | 08/16/2023 | Food and Beverage | Undisputed | 06/30/2026 | 997915779 | CMS |
| Amgen Inc. | $18.56 | 01/30/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1020663179 | CMS |
| Amgen Inc. | $16.88 | 04/11/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1020663181 | CMS |
| Amgen Inc. | $15.76 | 05/22/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1020663183 | CMS |
| Astellas Pharma US Inc | $15.43 | 07/10/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1034258117 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.52 | 05/19/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1015065829 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.77 | 08/28/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1000331327 | CMS |
| Exact Sciences Corporation | $18.85 | 01/26/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1026674703 | CMS |
| Exact Sciences Corporation | $30.08 | 10/06/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1026674791 | CMS |
| GlaxoSmithKline, LLC. | $18.66 | 01/12/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1001851249 | CMS |
| GlaxoSmithKline, LLC. | $15.08 | 01/20/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1001849339 | CMS |
| Novo Nordisk Inc | $12.72 | 02/17/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1000292183 | CMS |
| Novo Nordisk Inc | $13.29 | 07/14/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1000292191 | CMS |
| Novo Nordisk Inc | $15.17 | 09/15/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1000292197 | CMS |
| Novo Nordisk Inc | $16.59 | 11/03/2023 | Food and Beverage | Undisputed | 06/30/2026 | 1000292205 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.